The 2017 RARE Patient Advocacy Summit brings rare advocates from across the globe together to Connect, Collaborate, and Activate. This educational conference will be held Sept 14-15, 2017. Registration is available now.
Genome editing is a tool used in the laboratory setting to make changes to a organism's genetic material. A recent report from the National Academies of Sciences provides a review of the advances in this technology and offers recommendations for safe use of genome editing to improve human health. Yesterday a new Nature publication about the first human embryo gene editing in the US at OHSU stimulates discussion and controversy about the potential risks for future generations.
This targeted treatment study is for children and adolescents (ages 1 to 21) with solid tumors no longer responding to standard treatment or have recurred after treatment. The study matches patients with therapies aimed at molecular abnormalities in their tumors. Enrollment is available at children’s hospitals, university medical centers, and cancer centers across the US that are part of the Children's Oncology Group.
Presenter Katherine Bowman was study director for the recently released report on human genome editing. This webinar reported on the findings and recommendations of the National Academy of Sciences and National Academy of Medicine committee.
Obesity is a global health problem, contributing to premature death and morbidity by increasing a person's risk of developing diabetes, hypertension, heart disease and some cancers. While obesity mostly results from lifestyle and cultural factors, including excess calorie intake and inadequate levels of physical activity, it has a strong genomic component (NHGRI, 2017)
The advent of a powerful gene-editing tool called Crispr-Cas9 allows researchers to snip, insert and delete genetic material of humans with increasing precision. But should we? A new report out differs from perspectives in 2015.